Prof. Dr J. Lankelma


e-mail: jan.lankelma@falw.vu.nl

Room S522
Tel.: 020 59883870 / 59889439
Fax.: 020 5987229

full address:
Prof. Dr J. Lankelma
Tumor Cell Biology
Department of Molecular Cell Physiology
BioCentrum Amsterdam
Vrije Universiteit
De Boelelaan 1085
1081 HV Amsterdam (The Netherlands)

Research groups:

Current projects deal with:
see also http://www.vu-medicaloncology.org/

Selected publications:

  1. Huertas-Pérez JF, Heger M, Dekker H, Krabbe H, Lankelma J, Ariese F, Simple, rapid, and sensitive liquid chromatography-fluorescence method for the quantification of tranexamic acid in blood*, J Chromatogr A. 2007 Jul 20;1157(1-2):142-50)

  2. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. 2006. Cancer: a Systems Biology disease. Biosystems 83:81-90.
  3. Hornberg JJ, Bruggeman FJ, Binder B, Geest CR, de Vaate AJ, Lankelma J, Heinrich R, Westerhoff HV. Principles behind the multifarious control of signal transduction. ERK phosphorylation and kinase/phosphatase control. FEBS J. 2005, 272:244-258
  4. Hornberg JJ, Tijssen MR, Lankelma J. Synergistic activation of signalling to extracellular signal-regulated kinases 1 and 2 by epidermal growth factor and 4 beta-phorbol 12-myristate 13-acetate.Eur J Biochem. 2004 Oct;271(19):3905-13

  5. Korotkiy M, Middelburg R, Dekker H, van Harmelen F, Lankelma J. A tool for gene expression based PubMed search through combining data sources. Bioinformatics. 2004 Aug 12;20(12):1980-2.
    Link to the software: http://www.cs.vu.nl/microgenie/

  6. de Boer WP, Oudejans JJ, Meijer CJ, Lankelma J. Analysing gene expressions with GRANK. Bioinformatics. 2003 Oct 12;19(15):2000-1.

  7. Lankelma J. Tissue transport of anti-cancer drugs.Curr Pharm Des. 2002;8(22):1987-93.

  8. Wielinga PR, Westerhoff HV, Lankelma J. The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells. Eur J Biochem. 2000 Feb;267(3):649-57.

  9. Lankelma J, Dekker H, Luque FR, Luykx S, Hoekman K, van der Valk P, van Diest PJ, Pinedo HM. Doxorubicin gradients in human breast cancer. Clin Cancer Res. 1999 Jul;5(7):1703-7.

  10. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7690-4.

  11. Spoelstra EC, Westerhoff HV, Dekker H, Lankelma J. Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur J Biochem. 1992 Jul 15;207(2):567-79.

  12. van Groeningen CJ, Pinedo HM, Heddes J, Kok RM, de Jong AP, Wattel E, Peters GJ, Lankelma J. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res. 1988 Dec 1;48(23):6956-61.